Introduction {#s1}
============

Morphogenesis is guided by dynamic spatio-temporal regulation of gene expression patterns ([@bib7]; [@bib4]), the zones within tissues where genes are expressed during specific periods in development. Critical changes in the space, time or intensity of gene expression patterns can result in organ malformation, with reduced or even loss of function. These errors of morphogenesis, which occur in approximately 3% of live births ([@bib55]), are induced by environmental and/or genetic insults that alter the normal process of development. The common approach to revealing the origin of these alterations is to look for phenotypic abnormalities in animal models and to visually assess the overall patterns of gene expression. This qualitative approach has not, however, been able to identify the earliest signs of dysmorphogenesis in many diseases because the first changes in the gene expression patterns may be subtle, limited in time, and later abnormalities may obscure the original genetic cause. To reveal the primary etiology of congenital malformations, more rigorous methods are needed to quantify the three-dimensional (3D) phenotypes of gene expression patterns. A useful tool for tracing back development should be able to perform a quantitative statistical comparison of normal and disease-altered embryogenesis and to detect the earliest signs of genetic misregulation leading to organ malformation.

The shape of developing organs is regulated by gene activity in space and time ([@bib4]). Cascades of gene regulatory networks provide the detailed instructions necessary to organize cell behavior and to orchestrate tissue growth and differentiation. Gene expression patterns can be readily mapped within tissues in a true 3D framework combining whole-mount-in-situ hybridization (WMISH) ([@bib47]) with Optical Projection tomography (OPT) ([@bib50]). WMISH is a standard molecular technique for detecting the expression of a specific gene using a labeled complementary RNA probe ([@bib12]; [@bib11]), and OPT is a mesoscopic imaging procedure that can produce high-resolution 3D reconstructions of whole developing embryos processed by WMISH ([@bib51]; [@bib6]). These technologies represented breakthroughs in developmental biology and have provided invaluable qualitative insights into gene function and development ([@bib51]). However, methods for quantifying the 3D distributions of gene expression in a systematic, objective manner are still lacking.

Expanding the potential of OPT from *qualitative* to *quantitative* analysis of gene expression patterns is challenging. Gene expression is characterized by highly dynamic patterns, with fast rates of change and fuzzy boundaries that usually do not correspond to well-defined anatomical structures but rather to tissue regions where cells have dynamically up- and downregulated genes. Gene expression patterns have rarely been quantified ([@bib29]; [@bib3]; [@bib49]; [@bib39]; [@bib26]; [@bib61]; [@bib38]). We propose to quantify the shape of developing organs in association with their underlying gene expression patterns by applying Geometric Morphometrics (GM), a set of statistical tools for measuring and comparing shapes with increased precision and efficiency ([@bib28]; [@bib31]; [@bib33]; [@bib2]; [@bib19]). Previous attempts had analyzed the phenotypic and gene expression patterns of variation independently ([@bib29]), using different morphometric methods ([@bib26]; [@bib61]) or were restricted to two-dimensional analyses ([@bib38]). Therefore, the current study is the first to combine OPT and GM to characterize the shape of gene expression patterns quantitatively in 3D and to associate these changes to phenotypic changes. Thus, this approach provides the ability to replace qualitative observations with the quantification of subtle yet significant biological differences that underlie the processes through which morphogenesis is altered by disease.

Here, we illustrate how our method can reveal the genetic origin of developmental defects by investigating limb malformations in Apert syndrome \[OMIM 101200\]. Apert syndrome is a rare congenital disease, with a disease prevalence of 15--16 per million live births, that is characterized by cranial, neural, limb, and visceral malformations ([@bib10]). Over 99% of Apert cases are associated with one of two missense mutations, S252W or P253R, in the Fibroblast Growth Factor Receptor 2 (FGFR2) ([@bib59]; [@bib43]). The mutations occur on neighboring amino acids on the linker region between the second and third extracellular immunoglobulin domains of FGFR2, and alter the ligand-binding specificity of the receptors ([@bib64]; [@bib65]). Thus, the FGF receptors are activated inappropriately, altering the entire FGF/FGFR signaling pathway and causing dysmorphologies of different organs and systems ([@bib40]). Apert syndrome shares craniofacial dysmorphologies with other craniosynostosis syndromes but is differentiated on the basis of limb defects of the fore- and hindlimb digits. The craniofacial dysmorphology of Apert syndrome (i.e. premature closure of cranial sutures and patent anterior fontanelle associated with atypical head shape, midfacial retrusion and palatal defects) ([@bib10]) has been intensively investigated, especially because mouse models show cranial phenotypes that correspond with the human condition ([@bib22]; [@bib37]; [@bib23]; [@bib21]; [@bib20]). The associated limb defects are less well studied, however, in part because mouse models for Apert syndrome present only subtle limb anomalies ([@bib8]; [@bib57]; [@bib58]), even in mice carrying the P253R mutation ([@bib58]) which is associated with the more severe limb malformations in Apert syndrome ([@bib53]; [@bib56]).

Here, we present precise phenotyping of the limbs of newborn and embryonic specimens of the *Fgfr2^+/P253R^* Apert syndrome mouse model, and reveal significant differences that can be traced to as early as one day after the initiation of limb development. To explore the molecular basis of these initial signs of limb dysmorphology, we applied our method combining OPT and GM to assess the expression pattern of a downstream target of Fgf signaling, *Dusp6*. We chose to assess *Dusp6* because it is well-documented as a direct target of Fgf signaling ([@bib30]; [@bib35]; [@bib15]), and because, in addition to being a relevant gene for limb morphogenesis, it is also important for facial, brain and heart development ([@bib30]; [@bib35]; [@bib36]). Therefore, *Dusp6* was an ideal candidate for our proof-of-concept study. Our quantitative analyses demonstrate that the Apert syndrome *Fgfr2 P253R* mutation induces changes in the expression pattern of *Dusp6* and that these genetic changes are associated with significant phenotypic alterations. These results provide insight into the origins of limb malformations in Apert syndrome.

Results {#s2}
=======

Apert syndrome mice present limb malformations at birth {#s2-1}
-------------------------------------------------------

Previous studies have reported that most Apert syndrome mice do not show obvious abnormalities of the limbs ([@bib8]), and thus focused their molecular analyses on the skull ([@bib58]). Histopathological analyses in Apert syndrome mice revealed overall limb shortening resulting from abnormal osteogenic differentiation, but no signs of limb disproportion or syndactyly ([@bib57]; [@bib58]). Syndactyly has only been reported in three specimens of an outbred knock-in *Fgfr2^+/P253R^* model ([@bib63]), but no experimental analyses were performed to further explain why the FGFR2 mutation did not affect limb development in all the specimens within the sample.

As a further test of whether or not the *Fgfr2 P253R* mutation affects limb development in mice, we first performed an extensive quantitative analysis of the size and shape of individual forelimb bones using data from high resolution microCT images of newborn (P0) mutant and unaffected littermates ([Figure 1A--F](#fig1){ref-type="fig"}). Our results revealed many more significant differences between P0 unaffected and *Fgfr2^+/P253R^* mutant littermates than previously reported. We found that the humerus, radius and ulna were statistically significantly shorter in length but had increased bone volumes in *Fgfr2^+/P253R^* mutant mice in comparison to unaffected littermates ([Table 1](#table1){ref-type="table"} and [Figure 1G](#fig1){ref-type="fig"}). More localized size differences were detected in the bones derived from the autopod that give rise to the hands. The distal phalanx of digit I, the proximal phalanx of digit V, and metacarpals II, III and IV were significantly longer in *Fgfr2^+/P253R^* mutant mice ([Table 1](#table1){ref-type="table"} and [Figure 1G](#fig1){ref-type="fig"}). In contrast, the proximal phalanx of digit III was shorter and lower in bone volume in *Fgfr2^+/P253R^* Apert syndrome mice relative to unaffected littermates ([Table 1](#table1){ref-type="table"} and [Figure 1G](#fig1){ref-type="fig"}). The scapula and the clavicle, the bones that form the shoulder girdle, were also significantly affected: the scapula was longer, the clavicle was shorter and both bones showed increased bone volumes in *Fgfr2^+/P253R^* Apert syndrome mice ([Table 1](#table1){ref-type="table"} and [Figure 1G](#fig1){ref-type="fig"}) compared to unaffected littermates.

![Quantitative size and shape comparison of forelimb bones in *Fgfr2^+/P253R^* newborn mice (**P0**) and unaffected littermates.\
(**A**) Mouse skeleton at P0. 3D isosurface reconstruction of the skeleton of an unaffected littermate obtained from a high-resolution µCT scan. (B--F) Anatomical landmarks recorded on microCT scans of Apert syndrome mice at P0. (**B**) Autopod (hand). Landmarks were recorded at the midpoint of the proximal and distal tips of the distal, mid and proximal phalanges (P1--P28) and the metacarpals (P29--P38). Proximal phalanx I, middle phalanx V, and metacarpal I are not displayed because these bones have not yet mineralized at P0 and could not be visualized in many specimens. (**C**) Zeugopod. Landmarks were recorded at the midpoint of the proximal and distal tips of the radius (R1--R2) and ulna (U1--U2). (**D**) Stylopod. Landmarks were recorded at the midpoint of the proximal and distal tips of the humerus (H1--H2), as well as at the tip of the deltoid process (**H3**) ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). (**E**) Scapula. Landmarks were recorded at the most superior and inferior lateral points of the scapula (S1--S2), the most posterior point of the spine (**S3**), the most antero-medial point of the acromion process (**S4**) and the medial, superior and inferior points of the glenoid cavity (S5--S7) ([Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}). (**F**) Clavicle. Landmarks were recorded at the medial point of the sternal and the acromial ends (C1--C2). (**G**) Length and volume differences in the forelimbs of Apert syndrome mouse models. Schematic representation of the forelimb of a P0 mouse showing, in different colors, statistically significant differences in bone length and volume (as measured by two-tailed one-way ANOVA or Mann-Whitney U-test) in *Fgfr2^+/P253R^* mice and unaffected littermates, as specified in [Table 1](#table1){ref-type="table"}. Longer/shorter refers to length, whereas larger/smaller refers to volume. (**H, I**) Shape differences in the forelimbs of Apert syndrome mouse models. Scatterplots of PC1 and PC2 scores based on Procrustes analysis of anatomical landmark locations representing the shape of the left humerus (**H**) and the left scapula (**I**) of unaffected (N = 10) and mutant (N = 12) littermates of Apert syndrome mouse models ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"} and [Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}). Convex hulls represent the range of variation within each group of mice.\
10.7554/eLife.36405.004Figure 1---source data 1.Source files for humerus shape data.This zip archive contains the i) raw landmark coordinates registered to capture the shape of the humerus, as defined in [Figure 1D](#fig1){ref-type="fig"}; ii) the estimated centroid size and long-centroid size; iii) the Procrustes coordinates after Generalized Procrustes analysis (GPA); and iv) the PC scores resulting from the Principal Component Analysis (PCA) displayed in [Figure 1H](#fig1){ref-type="fig"}.\
10.7554/eLife.36405.005Figure 1---source data 2.Source files for scapula shape data.This zip archive contains the (i) raw landmark coordinates registered to capture the shape of the scapula, as defined in [Figure 1E](#fig1){ref-type="fig"}; (ii) the estimated centroid size and long-centroid size; iii) the Procrustes coordinates after Generalized Procrustes Analysis (GPA); and iv) the PC scores resulting from the Principal Component Analysis (PCA) displayed in [Figure 1I](#fig1){ref-type="fig"}.](elife-36405-fig1){#fig1}

10.7554/eLife.36405.006

###### Quantitative comparison of mean bone lengths and volumes.

Means were computed as the average lengths or volumes of the right and the left bones for *Fgfr2^+/P253R^* mutant (N = 12) and *Fgfr2^+/+^* unaffected (N = 10) mice. Data for proximal phalanx I, middle phalanx V, and metacarpal I are not listed because these bones were not present in all of the specimens, as they may not yet be developed at P0. Statistically significant differences as determined by two-tailed one-way ANOVA or Mann-Whitney U-tests are marked with \* (*P-value\<*0.05). Statistically significant differences after Bonferroni correction are indicated with \*\*.

                                                         Mean bone length (mm ± SD)                  Mean bone volume (mm^3^ ± SD)                                         
  ------------------------------- ---------------------- ---------------------------- -------------- ------------------------------- ------------------- ----------------- -----------
  **Autopod**                     **Distal phalanx I**   0.11 ± 0.03                  0.13 ± 0.02    0.004\*\*                       0.0015 ± 0.0008     0.0015 ± 0.0008   0.86
  **Distal phalanx II**           0.22 ± 0.03            0.21 ± 0.03                  0.128          0.0021 ± 0.0007                 0.0022 ± 0.0008     0.659             
  **Middle phalanx II**           0.004 ± 0.003          0.01 ± 0.004                 0.336          0.00002 ± 0.00002               0.00003 ± 0.00002   0.759             
  **Proximal phalanx II**         0.15 ± 0.01            0.14 ± 0.01                  0.057          0.0054 ± 0.0011                 0.0053 ± 0.0014     0.82              
  **Distal phalanx III**          0.26 ± 0.006           0.24 ± 0.01                  0.068          0.0034 ± 0.0008                 0.0033 ± 0.0017     0.796             
  **Middle phalanx III**          0.10 ± 0.006           0.10 ± 0.006                 0.243          0.0019 ± 0.0009                 0.0022 ± 0.0013     0.436             
  **Proximal phalanx III**        0.204 ± 0.02           0.18 ± 0.03                  0.001\*\*      0.0087 ± 0.0003                 0.0073 ± 0.0004     0.016\*           
  **Distal phalanx IV**           0.24 ± 0.006           0.19 ± 0.02                  0.061          0.0024 ± 0.0009                 0.0024 ± 0.0014     0.923             
  **Middle phalanx IV**           0.06 ± 0.009           0.07 ± 0.01                  0.338          0.0009 ± 0.0002                 0.0014 ± 0.0002     0.24              
  **Proximal phalanx IV**         0.20 ± 0.01            0.20 ± 0.02                  0.412          0.0080 ± 0.0016                 0.0075 ± 0.0021     0.358             
  **Distal phalanx V**            0.09 ± 0.01            0.08 ± 0.01                  0.832          0.0005 ± 0.00007                0.0006 ± 0.0001     0.769             
  **Proximal phalanx V**          0.14 ± 0.01            0.15 ± 0.02                  0.027\*        0.0031 ± 0.0007                 0.0036 ± 0.0012     0.089             
  **Metacarpal II**               0.39 ± 0.02            0.41 ± 0.02                  0.034\*        0.0270 ± 0.0028                 0.0265 ± 0.0034     0.586             
  **Metacarpal III**              0.49 ± 0.03            0.52 ± 0.03                  0.004\*        0.0398 ± 0.0043                 0.0382 ± 0.0062     0.342             
  **Metacarpal IV**               0.43 ± 0.02            0.45 ± 0.03                  0.011\*        0.0312 ± 0.0033                 0.0291 ± 0.0048     0.114             
  **Metacarpal V**                0.22 ± 0.01            0.22 ± 0.02                  0.571          0.0120 ± 0.0019                 0.0124 ± 0.0023     0.458             
  **Zeugopod**                    **Radius**             2.29 ± 0.02                  2.22 ± 0.01    0.003\*                         0.3187 ± 0.0292     0.3558 ± 0.0334   0.001\*\*
  **Ulna**                        2.76 ± 0.08            2.64 ± 0.07                  0.000\*\*      0.4999 ± 0.0417                 0.5366 ± 0.0766     0.010\*           
  **Stylopod**                    **Humerus**            1.65 ± 0.01                  1.62 ± 0.007   0.007\*                         0.9950 ± 0.0764     1.1444 ± 0.0649   0.001\*\*
  **Not derived from limb bud**   **Scapula**            2.69 ± 0.08                  2.75 ± 0.06    0.013\*                         1.0757 ± 0.0733     1.2184 ± 0.0777   0.001\*\*
  **Clavicle**                    2.47 ± 0.06            2.34 ± 0.09                  0.001\*\*      0.2214 ± 0.0147                 0.2811 ± 0.0232     0.001\*\*         

The Principal Components Analysis (PCA) based on the shape of the humerus did not show marked shape differences between unaffected and *Fgfr2^+/P253R^* Apert syndrome mice ([Figure 1H](#fig1){ref-type="fig"}). However, the PCA of the scapula indicated a clear morphological differentiation between these two groups ([Figure 1I](#fig1){ref-type="fig"}). The scapula of *Fgfr2^+/P253R^* Apert syndrome mice presented a more robust phenotype, with wider and longer scapulae, in comparison to that of their unaffected littermates.

Overall, these size and shape differences demonstrate that *Fgfr2^+/P253R^* Apert syndrome mice present widespread and significant limb dysmorphologies at P0 that were not previously reported and would not have been revealed without microCT scanning and quantitative statistical testing. Some defects, such as shoulder anomalies and short humeri, have a direct correspondence with the human phenotype ([@bib43]). In newborn mice, however, we did not detect any clear sign of syndactyly, which is the most prominent limb defect in people with Apert syndrome ([@bib9]; [@bib24]). As the forelimb of mice is not yet completely ossified at P0 and because *Fgfr2^+/P253R^* mutant littermates die shortly after birth, we could not assess whether other limb abnormalities might appear later in development.

A quantitative morphometric method to assess embryonic gene expression patterns {#s2-2}
-------------------------------------------------------------------------------

To determine the earliest developmental basis of the limb anomalies quantified in newborn mice, we developed a quantitative method to explore early embryonic limb development. First, to visualize the expression pattern of a downstream target of *Fgfr2,* we obtained OPT scans of *Fgfr2^+/P253R^* Apert syndrome mouse embryos that had been analyzed with WMISH to reveal *Dusp6* expression ([Figure 2](#fig2){ref-type="fig"}). Qualitative assessment of the 3D reconstructions showed that *Dusp6* was widely expressed throughout the embryo from embryonic day (E)10.5 to E11.5, with highest intensity in the limbs, the head and the somites ([Figure 2](#fig2){ref-type="fig"}). *Dusp6* was also expressed in the heart with moderate intensity. By comparing the distribution of the *Dusp6* gene expression pattern visually, it was possible to distinguish between embryos at the E10.5 and the E11.5 stages of development. At E10.5, *Dusp6* was prominently expressed in the facial prominences and in the forming somites along most of the craniocaudal segment, whereas at E11.5, the expression of *Dusp6* was more widespread in the brain and restricted to the caudal somites. Focusing on the limbs, the expression of *Dusp6* at the two different stages was also readily distinguishable, with *Dusp6* expression domains thinning into a more extended domain along the limb outline as the limb buds grow from E10.5 to E11.5 ([Figure 2](#fig2){ref-type="fig"}). The limb bud expression patterns of *Fgfr2^+/P253R^* mutant and unaffected littermates were not distinguishable because of the large amount of developmental variation within litters ([Figure 2](#fig2){ref-type="fig"}).

![Qualitative visualization of *Dusp6* gene expression in unaffected and *Fgfr2^+/P253R^* mouse embryos at E10.5 and E11.5.\
OPT scans of embryos WMISH stained for *Dusp6* revealed the anatomical location of *Dusp6* gene expression (shown in yellow). For each stage, the main expression domains are highlighted on the left for anatomical reference on a lateral view of a 3D reconstruction of a *Fgfr2^+/+^* unaffected embryo (fb, forebrain; fl, forelimb; hb, hindbrain; hl, hindlimb; ht, heart; is, isthmus; lnp, lateral nasal process; md, mandibular prominence; mnp, medial nasal process; mx, maxillary prominence; so, somites). On the right, 3D reconstructions of three unaffected and three *Fgfr2^+/P253R^* mutant embryos from the same litter are displayed to represent the high degree of variation in developmental age within litters. Embryos are not to scale. Original 2D images of the *Dusp6* WMISH experiments are available in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.36405.008Figure 2---source data 1.Original 2D images of the *Dusp6* WMISH experiments.This zip archive contains pictures, taken using a Leica MX16F microscope, of the right and left sides of the mouse embryos that underwent *Dusp6* WMISH. Folders are organized by developmental stage and genotype.](elife-36405-fig2){#fig2}

Quantitative testing was thus required to allow the more accurate evaluation of limb alterations that are potentially associated with Apert syndrome but visually undetectable. We developed a method for 3D shape analysis of the limb and the associated gene expression pattern of *Dusp6* ([Figure 3](#fig3){ref-type="fig"}). This protocol enabled us to determine differences in limb size and shape between genotype groups and to assess whether these phenotypic differences are associated with altered gene expression patterns ([Figure 3](#fig3){ref-type="fig"}). Our approach uses GM methods to measure directly the limb anatomy and gene expression domains segmented from the 3D reconstructions of the embryo OPT scans. As expression of *Dusp6* showed a fuzzy spatial gradient, multiple thresholding was used to define a consistently high gene expression pattern ([Figure 3](#fig3){ref-type="fig"}, steps from 1 to 5). After manual and semiautomatic recording of the 3D coordinates of landmarks on the surfaces of the limb and the gene expression domains blinded to group allocation ([Figure 3](#fig3){ref-type="fig"}, step 6; [Video 1](#video1){ref-type="video"}), multivariate statistical analyses were performed to explore shape and size variation and covariation patterns for the limb morphology and the *Dusp6* domain ([Figure 3](#fig3){ref-type="fig"}, steps 7 and 8).

![New quantitative analysis method for 3D gene expression data, based on Geometric Morphometrics.\
Mouse embryos between E10.5 and E11.5 were analyzed with WMISH to reveal the expression of *Dusp6* (1), and then cleared with BABB, and OPT scanned using both fluorescence and transmission light (2). The external surface of the embryo was obtained from the 3D reconstruction of the fluorescence scan (2). Multiple thresholding of the transmission scan by choosing different levels of grey values as shown by the histogram allowed the visualization of gene expression patterns at different intensities (3). Moderate gene expression (shown in green) was displayed as the isosurface obtained using a threshold of the grey value computed as 2/3 of the last grey value showing the *Dusp6* expression domain (3). High gene expression (shown in yellow) was displayed as the isosurface obtained using a threshold of the grey value computed as 1/3 of the last grey value showing the *Dusp6* expression domain (3). From the whole mouse embryo isosurfaces, all four limb buds were segmented (5A). From the high gene expression isosurface, the *Dusp6* domains from all of the available limbs were segmented (5B). Maximum curvature patterns were displayed to optimize landmark recording (5). For each limb, we captured the shape and size of the limb bud (6A) and the underlying high *Dusp6* gene expression pattern (6B), recording the 3D coordinates of anatomical landmarks (yellow dots), curve semi-landmarks (red dots) and surface semi-landmarks (pink dots). Anatomical and curve landmarks were recorded manually on each limb. Surface landmarks were recorded on one template limb and interpolated onto target limbs ([Video 1](#video1){ref-type="video"}). Landmark coordinates were the input for Geometric Morphometric (GM) quantitative shape analysis (7, 8) that was used to superimpose the landmark data (GPA, Generalized Procrustes Analysis), to compute limb size (centroid size), and to explore both shape variation within limbs and gene expression domains within litters by Principal Component Analysis (PCA). Finally, the covariation patterns for the shape of the limb and the shape of the gene expression domain were also explored using the Partial Least Squares (PLS) method.](elife-36405-fig3){#fig3}

###### Morphometric approach for the analysis of 3D gene expression data obtained by Optical Projection Tomography.

In this video, we show a superimposed view of a fluorescent and a transmission OPT scan of the same E11.5 mouse embryo, which was analyzed with WMISH to reveal the gene expression of *Dusp6*, a downstream target of Fgf signaling. The surface of the mouse embryo rotating around its central axis was obtained from the 3D reconstruction of an OPT scan based on fluorescence light. The expression pattern of the *Dusp6* gene was segmented from the transmission OPT scan using multiple thresholding. The imaging revealed the anatomical location of regions of high *Dusp6* gene expression (shown in purple). To compare unaffected and *Fgfr2^+/P253R^* mouse embryos and to detect statistically significant differences between them, we collected landmarks along the surface of the gene expression domain (yellow dots) and the limb bud (green dots), which capture the size and shape of the limb and the underlying gene expression domain to a highly accurate level of detail. Further quantitative analyses provided insight into the origins of limb malformations in Apert syndrome.

10.7554/eLife.36405.010

The first signs of limb dysmorphology in Apert syndrome {#s2-3}
-------------------------------------------------------

As gene expression patterns are highly dynamic and rapidly change in size, shape and position within a few hours as development progresses ([@bib38]), individual limb buds from *Fgfr2^+/P253R^* mutant embryos and their unaffected littermates aged between E10.5 and E11.5 were staged using a fine-resolution staging system (<https://limbstaging.embl.es>) ([@bib42]). The staging results showed that the analyzed limbs represent a temporal continuum throughout development, with no significant differences between the staging of unaffected and mutant littermates of the same litter ([Figure 4](#fig4){ref-type="fig"}). We partitioned the time span from E10 to E11.5 into four periods, each one approximately representing 12 hr of development (see [Table 2](#table2){ref-type="table"} and \'Materials and methods\' for further details on sample composition).

![Developmental variation within litters of the Apert syndrome mouse model.\
All of the limbs were individually staged using our publicly available web-based staging system (<https://limbstaging.embl.es>). The stage of the limb bud was estimated after alignment and shape comparison of the spline with an existing dataset with a reproducibility of ±2 hr. As both Litter 1 and Litter 2 comprised limbs between E10 and E10.5, we pooled these limbs into the \'Early\' period. Litter 3, comprising limbs between E10 and E11, represented the \'Mid\' developmental period. And finally, Litter 4, which included limbs between E11 and E11.5, was considered as the \'Late\' period. In subsequent analyses, forelimbs and hindlimbs were analyzed separately, as specified in [Table 2](#table2){ref-type="table"}. Increasing color intensities in dots represent an increasing number of limbs with the same staging result. Individual scores are available in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.36405.012Figure 4---source data 1.Staging results.Table containing the individual scores obtained from the staging system and used to produce the graph in [Figure 4](#fig4){ref-type="fig"}.](elife-36405-fig4){#fig4}

10.7554/eLife.36405.013

###### Sample composition by genotype and period.

*Fgfr2^+/+^*: unaffected littermates; *Fgfr2^+/P253R^*: Apert syndrome mutant littermates. Developmental periods were defined according to limb staging, as shown in [Figure 4](#fig4){ref-type="fig"}. Hindlimbs and forelimbs were analyzed separately because, in the same embryo, hindlimbs are delayed in development in comparison to forelimbs by about 6--8 hr. We thus presented in the main text the results from groupings highlighted in color, including those for the hindlimbs from the early and mid groups, as well as those for the forelimbs from the mid and the late groups. This represents a continuous time span of limb development, from E10 to E11.5, divided into four periods of 12 hr each. Results from the complete dataset that considers hindlimbs and forelimbs from each litter separately are available in [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"} ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}, [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}).

  **Genotype**           **Period**             **N limb**   **N gene**   **LIMB**                                                              
  ---------------------- ---------------------- ------------ ------------ ------------------------- ---------------------- -------------------- ----------
                                                                          **Early (\~E10)**                                                     
                                                                          **Limb**                  **Gene**               **Limb**             **Gene**
  ***Fgfr2^+/+^***       **EARLY: E10-E10.5**   30           24           13                        9                      17                   15
  ***Fgfr2^+/P253R^***   16                     15           11           9                         5                      6                    
  **Subtotal**           46                     39           24           18                        22                     21                   
                                                                          **Mid early (\~E10.5)**   **Mid late (\~E11)**                        
                                                                          **Limb**                  **Gene**               **Limb**             **Gene**
  ***Fgfr2^+/+^***       **MID: E10.5-E11**     15           10           7                         3                      8                    7
  ***Fgfr2^+/P253R^***   16                     9            8            3                         8                      6                    
  **Subtotal**           31                     19           15           6                         16                     13                   
                                                                                                                           **Late (\~E11.5)**   
                                                                          **Limb**                  **Gene**               **Limb**             **Gene**
  ***Fgfr2^+/+^***       **LATE: E11-E11.5**    8            8            4                         4                      4                    4
  ***Fgfr2^+/P253R^***   15                     14           7            6                         8                      8                    
  ***Subtotal***         23                     22           11           10                        12                     12                   
  **Total**                                     100          80                                                                                 

We first focused on analyzing limb dysmorphology, aiming to determine the youngest stage at which there were morphological differences between mutant and unaffected limbs. To find the earliest moment when differences arise, we traced limb development backwards in time using Geometric Morphometric methods, starting first with embryos from the oldest period (as the differences would be easier to find) and from there proceeding towards the earlier (younger) periods. In this way, we should be able to identify confidently the initiation of limb dysmorphogenesis associated with the *Fgfr2 P253R* mutation.

During the \'Late\' period, we detected that *Fgfr2^+/P253R^* limb buds were already clearly separated from those of their unaffected littermates in the morphospace defined by the Principal Component Analysis (PCA) ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Relative to those of their unaffected littermates, the limbs of *Fgfr2^+/P253R^* mice presented subtle phenotypic limb differences: limbs were shorter and thicker, with limited development of the wrist ([Figure 5A](#fig5){ref-type="fig"}). Quantitative comparison of limb size showed that the limbs of mutant mice were also significantly smaller than those of their unaffected littermates ([Table 3](#table3){ref-type="table"} and [Figure 6A](#fig6){ref-type="fig"}). Interestingly, in this \'Late\' period the limbs of mutant mice were smaller than unaffected littermates (although this was not the case in earlier periods). Overall, these results confirmed that the *Fgfr2 P253R* Apert syndrome mutation has an effect on limb development, altering both the size and shape of the limbs. These subtle but significant phenotypic differences would most probably have remained undetected by a qualitative approach. Our quantitative approach revealed their statistical significance and pointed to the origin of the Apert syndrome limb malformation prior to E11.5, before the \'Late\' period.

![Tracing of limb phenotypes (anatomical and molecular) back through developmental time to the earliest moment of appearance.\
Principal Component Analysis based on the Procrustes-based semi-landmark analysis was used to assess the shape of the limbs and the corresponding *Dusp6* expression domains for each developmental period ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Each period was analyzed separately for the shape of the limb (A--D) and the *Dusp6* expression domain (E--H), as specified in the [\']{.ul}Materials and methods[\']{.ul} and in [Table 2](#table2){ref-type="table"}. Scatterplots of PC1 and PC2 axes with the corresponding percentages of total morphological variation explained are displayed for each analysis, along with the morphings associated with the negative, mid and positive values of the PC axis that separates mutant and unaffected littermates (PC1 or PC2, as highlighted in bold black letters in the corresponding axis). Morphings are displayed in grey tones when the analysis showed no differentiation between mutant and unaffected littermates. Morphings are displayed in color when the analysis revealed differentiation between mouse groups (blue: unaffected littermates; pink: mutant littermates). Limb buds and *Dusp6* domains are not to scale and are oriented with the distal aspect to the left, the proximal aspect to the right, the anterior aspect at the top and the posterior aspect at the bottom of all images. Convex hulls represent the ranges of variation within each group of mice. Individual scores are available in [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}. Results from the complete dataset analyzing hindlimbs ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}, [Figure 5---figure supplement 2---source data 1](#fig5s2sdata1){ref-type="supplementary-material"}) and forelimbs ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}, [Figure 5---figure supplement 3---source data 1](#fig5s3sdata1){ref-type="supplementary-material"}) from each litter separately are also available.\
10.7554/eLife.36405.020Figure 5---source data 1.Source files for limb shape data.This zip archive contains the (i) raw landmark coordinates registered to capture the shape of the limbs and the associated *Dusp6* expression domains, as defined in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}; (ii) the estimated centroid size and long-centroid size of each structure; (iii) the Procrustes coordinates after Generalized Procrustes Analysis (GPA); and iv) the PC scores resulting from each of the Principal Component Analyses (PCA) displayed in [Figure 5](#fig5){ref-type="fig"}.](elife-36405-fig5){#fig5}

![Quantitative correlation between the size and shape of the limbs and the *Dusp6* expression pattern.\
(**A--D**) Comparison of limb bud size and *Dusp6* volume in unaffected and *Fgfr2^+/P253R^* mutant littermates across development ([Table 3](#table3){ref-type="table"}). Limb size was measured as limb centroid size (**A**), whereas the size of the *Dusp6* expression was measured as the volume of the gene domain (**B**), as specified in the \'Materials and methods\' and in [Table 2](#table2){ref-type="table"}. Statistically significant differences as revealed by two-tailed t-tests are marked with asterisks, representing the degree of significance: \**P-value*=0.03, \*\**P-value*=0.01. Results from hindlimbs and forelimbs are separately available in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}. The association between the size of the limbs and the volume of the *Dusp6* domain was assessed separately for forelimbs (**C**) and hindlimbs (**D**). Individual scores for all of these analyses are available in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}. (**E**) Time course assessing the morphological integration pattern between the limb phenotype and the shape of the gene expression pattern using partial least squares analyses. Associated shape changes from late to early limb development are shown from morphings associated with the negative, mid and positive values of PLS1, which accounted for almost all of the covariation (97.6% in forelimbs and 99.5% in hindlimbs) between the limb buds and the *Dusp6* gene expression domains ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Limb buds and *Dusp6* domains are not shown to scale and are oriented distally to the left, proximally to the right, anteriorly to the top and posteriorly to the bottom. On the right, representing the positive extreme of PLS1 axis, typical early limb buds showed a protruding shape (i.e. short in the proximo-distal axis and symmetrical in the antero-posterior axis) associated with a flat-bean shaped *Dusp6* expression zone localized in the distal limb region, underlying the apical ectodermal ridge and spreading proximally towards the dorsal and ventral sides of the limb. On the left, representing the negative extreme of the PLS1 axis, limb buds were elongated in the proximal axis and asymmetric on the antero-posterior axis, with an expansion of the distal limb region and a contraction of the proximal region, at the wrist level. This limb shape, which is typical of more developed limbs, was associated with a *Dusp6* expression that was extended underneath the apical ectodermal ridge towards the anterior and the posterior ends of the gene expression zone, but reduced on the dorsal and ventral sides of the limb. Individual scores for all of these analyses are available in [Figure 6---figure supplement 2---source data 1](#fig6s2sdata1){ref-type="supplementary-material"}. Legends for supplementary figures.\
10.7554/eLife.36405.025Figure 6---source data 1.Source files for limb size and gene expression volume.This Excel file contains tables with the individual scores for limb centroid size (µm) and *Dusp6* volume (µm^3^) used to produce the graphs in (i) [Figure 6A](#fig6){ref-type="fig"} and [Figure 6B](#fig6){ref-type="fig"}; (ii) [Figure 6C](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1B,D](#fig6s1){ref-type="fig"}; and (iii) [Figure 6D](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A,C](#fig6s1){ref-type="fig"}.](elife-36405-fig6){#fig6}

10.7554/eLife.36405.026

###### Quantitative comparison of limb size (μm) and *Dusp6* volume (μm^3^) in *Fgfr2^+/P253R^* mutant and *Fgfr2^+/+^* unaffected mice.

Results from two-sided t-tests are provided separately for forelimbs and hindlimbs and for each developmental group, as defined in [Table 2](#table2){ref-type="table"} and [Figure 4](#fig4){ref-type="fig"}. Statistically significant differences are marked with \* (*P-value\<*0.05).

                               **EARLY**          **MID**                **LATE**                                                                                                                                                                  
  ---------------- ----------- ------------------ ---------------------- ---------- -------- --------------- ------------------ ---------------------- ------- -------- --------------- ------------------ ---------------------- ------- -------- ---------------
  Forelimb         Limb size   2041.63            2274.15                6.99       18.98    \<0.0001        2728.24            2579.69                −1.70   7.74     0.13            3311.66            3097.72                −3.57   5.39     0.01
  *Dusp6* volume   18160720    18387239           0.13                   13.03      0.89     23002206        27432909           1.78                   9.64    0.11     24792568        29875554           2.47                   9.72    0.03     
                               **EARLY**          **MID**                **LATE**                                                                                                                                                                  
                               ***Fgfr2^+/+^***   ***Fgfr2^+/P253R^***   **t**      **df**   ***P-value***   ***Fgfr2^+/+^***   ***Fgfr2^+/P253R^***   **t**   **df**   ***P-value***   ***Fgfr2^+/+^***   ***Fgfr2^+/P253R^***   **t**   **df**   ***P-value***
  Hindlimb         Limb size   2280.36            2489.62                2.68       15.76    0.02            2769.51            2589.95                −1.74   3.03     0.18            3191.12            2955.91                −3.44   6.73     0.01
  *Dusp6* volume   16294103    16277958           −0.01                  15.36      0.99     23920390        23131303           −0.19                  2.45    0.86     41802827        45608477           0.52                   4.14    0.63     

During the \'Mid late\' period, the limbs of *Fgfr2^+/P253R^* mutant mice were still distinguishable from those of unaffected mice in the morphospace of the PCA ([Figure 5B](#fig5){ref-type="fig"}). At this period, the limbs of *Fgfr2^+/P253R^* mice lacked the antero-posterior asymmetry and the narrowing of the wrist region more typical of unaffected littermates. Instead, *Fgfr2^+/P253R^* mice showed a limb phenotype that was elongated in the proximo-distal axis and thickened in the dorso-ventral axis ([Figure 5B](#fig5){ref-type="fig"}), resembling the limb shape of younger unaffected embryos. This shape difference coincided with reduced growth in *Fgfr2^+/P253R^* mice, as the limbs of *Fgfr2^+/P253R^* mice tended to be smaller than unaffected limbs ([Table 3](#table3){ref-type="table"} and [Figure 6A](#fig6){ref-type="fig"}). Therefore, significant differences between unaffected and mutant limbs could still be detected during the \'Mid late\' period of development and the origins of limb defects associated with Apert syndrome should be sought earlier in development.

The first period during which no significant differences could be detected between unaffected and *Fgfr2^+/P253R^* Apert syndrome mice was at the \'Mid early\' period ([Figure 5C](#fig5){ref-type="fig"}). Despite internal variation in limb shape, with *Fgfr2^+/P253R^* mice spreading throughout the morphospace and unaffected littermates concentrated on one region, mutant and unaffected littermates completely overlapped. Therefore, limb shape differences could no longer be detected between groups. Limb size differences were not significant either ([Table 3](#table3){ref-type="table"} and [Figure 6A](#fig6){ref-type="fig"}). Therefore, our results suggest that the critical time point of limb dysmorphogenesis associated with Apert syndrome occurred between the \'Mid late\' and \'Mid early\' periods, corresponding to the transition period from E10.5 to E11 ([Figure 5B--C](#fig5){ref-type="fig"}).

Consistent with the above, no further sign of limb shape dysmorphology was detected during the \'Early\' period of development ([Figure 5D](#fig5){ref-type="fig"}). During this period, there was a great range of developmental variation, with unaffected and *Fgfr2^+/P253R^* mutant mice completely overlapping in the morphospace and with all limbs displaying similar incipient bud shapes ([Figure 5D](#fig5){ref-type="fig"}). The limbs of *Fgfr2^+/P253R^* mice were significantly larger than the limbs of their unaffected littermates ([Table 3](#table3){ref-type="table"} and [Figure 6A](#fig6){ref-type="fig"}), suggesting that at this early time point, there is a significant effect of the *Fgfr2 P253R* mutation on limb size but not on limb shape ([Figure 6A](#fig6){ref-type="fig"}).

*Fgfr2* Apert syndrome mutation leads to aberrant overexpression of *Dusp6* domains {#s2-4}
-----------------------------------------------------------------------------------

We next sought to obtain direct evidence of altered genetic regulation that could explain the observed limb phenotype by analyzing the shape dynamics of the expression of *Dusp6*, a direct target gene of Fgf signaling. As in the limb shape analysis described above, we chose to work backwards in developmental time, first examining the gene expression of *Dusp6* in the embryos from the latest period. We found that in the \'Late\' period, *Dusp6* expression was already different in *Fgfr2^+/P253R^* mutant mice and unaffected littermates. The differences were significant both in shape ([Figure 5E](#fig5){ref-type="fig"}) and size ([Table 3](#table3){ref-type="table"} and [Figure 6B](#fig6){ref-type="fig"}). In the limbs of unaffected mice, the *Dusp6* expression domain appeared as a thin domain underlying the apical ectodermal ridge, whereas in *Fgfr2^+/P253R^* mutant mice, the shape of the *Dusp6* domain was expanded in all directions ([Figure 5E](#fig5){ref-type="fig"}). Accordingly, the volume of the *Dusp6* expression domain was significantly larger in Apert syndrome mice ([Table 3](#table3){ref-type="table"} and [Figure 6B](#fig6){ref-type="fig"}), even when these mice had significantly smaller limbs ([Figure 6A](#fig6){ref-type="fig"}). The *Dusp6* expression domain thus grew disproportionately in the limbs of *Fgfr2^+/P253R^* mutant mice in the latest period of development ([Figure 5E](#fig5){ref-type="fig"}), which is consistent with reports of whole-body size reduction in *Fgfr2^+/P253R^* Apert mice and of the over-activation of *Fgfr2* signaling by the Apert syndrome mutation ([@bib65]; [@bib27]).

During the \'Mid late\' period, the shapes of expression patterns were still distinct --- the expanded *Dusp6* expression domain persisted on the dorsal and ventral sides of mutant limbs, but was reduced on the anterior and posterior sides ([Figure 5F](#fig5){ref-type="fig"}). The overall volume of the *Dusp6* expression domains remained larger in *Fgfr2^+/P253R^* mutant mice, but the difference was no longer statistically significant ([Table 3](#table3){ref-type="table"} and [Figure 6B](#fig6){ref-type="fig"}).

During the \'Mid early\' period, the separation between unaffected and *Fgfr2^+/P253R^* mutant mice was maintained in the PCA analysis ([Figure 5G](#fig5){ref-type="fig"}). Unaffected mice showed a *Dusp6* expression domain that was expanded towards the anterior and posterior edges of the expression domain ([Figure 5G](#fig5){ref-type="fig"}). By contrast, *Fgfr2^+/P253R^* mutant mice did not show the extension and the posterior asymmetry of the *Dusp6* expression domain typical of normal limb development, suggesting a lack of differentiation in the *Dusp6* expression of mutant limbs ([Figure 5G](#fig5){ref-type="fig"}).

The \'Early\' period was the only time point when we did not detect a significant difference between unaffected and *Fgfr2^+/P253R^* mice ([Figure 5H](#fig5){ref-type="fig"}). The PCA showed variation in the expression domains of *Dusp6,* with similar gene expression patterns in terms of both shape ([Figure 5H](#fig5){ref-type="fig"}) and size ([Table 3](#table3){ref-type="table"} and [Figure 6B](#fig6){ref-type="fig"}) across all mice. Therefore, the first observation of an alteration in the gene expression pattern ([Figure 5G](#fig5){ref-type="fig"}) occurred earlier than the change in the limb shape ([Figure 5B](#fig5){ref-type="fig"}). Our analyses provide evidence that differences in the *Dusp6* gene expression pattern first occurred during the \'Mid early period\', preceding the phenotypic limb differentiation, which occurred a few hours later during the \'Mid late period\'. Overall, the time courses showing the dynamics of limb shape and gene expression pattern changes throughout development ([Figure 5](#fig5){ref-type="fig"} and [Figure 6](#fig6){ref-type="fig"}) confirmed that the *Fgfr2* Apert syndrome mutation causes an aberrant overexpression of *Dusp6* early in development, which could later lead to significant limb malformations.

Altered *Dusp6* expression and limb dysmorphology are highly associated {#s2-5}
-----------------------------------------------------------------------

Finally, we explored the patterns of correlation between the limb phenotype and gene expression to further explore how altered Fgf signaling relates to the limb malformations induced by the Apert syndrome *Fgfr2 P253R* mutation. First, we assessed the relationship between the size of the limbs and the volume of the *Dusp6* expression domain, pooling all the forelimbs and hindlimbs and assessing the correlation between these two traits ([Figure 6C,D](#fig6){ref-type="fig"}). The trend line showed that for the same limb size, *Fgfr2^+/P253R^* mutant mice showed larger *Dusp6* expression domains, both in forelimbs (R^2^ = 0.4) and hindlimbs (R^2^ = 0.6). If the extension of the *Dusp6* expression depended only on limb growth, and the gene domain passively became larger by just following limb tissue growth, a higher correlation between the size of the limb and the gene expression would be expected. However, the moderate correlation found here suggests that the size of the *Dusp6* gene expression zone is not solely dependent on limb growth but might be controlled by further genetic regulatory factors.

Second, we assessed the morphological integration between the shape of the limbs and the shape of the *Dusp6* expression domain. The statistical analysis of the covariance pattern between these shapes can reflect the interaction of the phenotype and the gene expression pattern during limb development. As shown by analysis of additional genes expressed during limb development ([@bib38]), even when a gene is expressed within the limb, the shape of the limb and the shape of the gene expression domain are not correlated by definition, and the integration pattern can change from a strong association to no significant correlation within few hours as the limb develops ([@bib38]). The dynamics of the integration pattern can identify the key periods during which the expression of a gene is relevant for determining the shape of the limb. If the morphological integration is low, the expression of the gene will not be as relevant for determining the shape of the limb as it would be when the integration is high and the impact of the altered gene expression on the phenotype is minimal. If the morphological integration is high, the impact of the genetic mutation will be maximized (i.e. changes in the gene expression pattern will produce changes in the limb shape). Our results showed that the shape of the limb and the shape of the *Dusp6* expression domain were indeed highly correlated (RV = 0.88 in forelimbs; RV = 0.91 in hindlimbs). This is evidence that altered Fgf signaling, induced by the *Fgfr2 P253R* Apert syndrome mutation, can be associated with limb dysmorphology.

By comparing the morphological integration patterns in mutant and unaffected littermates during different periods, we can test whether this interaction is maintained or disrupted by the disease during development. If the pattern or magnitude of morphological integration is different in mutant mice, it should reveal further mechanisms underlying the etiology of the disease. Our analyses showed that the pattern of morphological integration of the shape of the limbs and the shape of the *Dusp6* expression domains was similar in unaffected and *Fgfr2^+/P253R^* mutant mice ([Figure 6E](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Our results confirmed that the *Fgfr2 P253R* mutation does not disrupt the strong association between limb shape and the *Dusp6* expression domain. Therefore, the alteration of the *Dusp6* expression pattern between E10 and E11.5, caused by the *Fgfr2* mutation, will correlate with the limb dysmorphologies associated with Apert syndrome. Overall, the high correlation between the shape of the limb and the *Dusp6* expression domain provides further evidence that altered Fgf expression resulting from the *Fgfr2* mutation is strongly associated with limb defects in Apert syndrome.

Discussion {#s3}
==========

By definition, revealing the primary etiology of an abnormality requires going back in time to the earliest moment when abnormal development can be found. Typically, the earliest changes will be the most subtle, and so the most statistically sensitive techniques are necessary to reveal these changes. The methods that are currently used to assess gene expression patterns are mainly qualitative and focus only on shape and size differences that can be simply detected by eye. Therefore, slight changes in gene expression domains, even if they have large effects on the phenotype ([@bib25]), can remain undetected. To reveal these subtle changes, we have developed a precise method combining OPT and GM to quantify embryo morphology and the underlying 3D gene expression patterns in a systematic, objective manner. This enables the visualization and quantification of how the genotype translates into the phenotype during embryonic development, the comparison of normal and disease-altered patterns of genetic and phenotypic variation and, eventually, the identification of the origins of abnormal morphogenesis. This approach can further our understanding of the etiology of genetic diseases in research using animal models ([@bib54]; [@bib48]), even in models that do not seem to recapitulate the human disease faithfully ([@bib16]).

Our study of the *Fgfr2 P253R* mouse model for Apert syndrome is an exemplary case demonstrating how quantitative assessment can overcome the shortcomings of traditional qualitative morphological assessment and lead to new discoveries. To date, the molecular and developmental mechanisms underlying the limb defects associated with Apert syndrome have remained obscure, even when these limb abnormalities clinically differentiate Apert syndrome from other craniosynostosis syndromes (such as Pfeiffer, Crouzon and Saethre-Chotzen syndromes) ([@bib43]; [@bib24]; [@bib10]). Most Apert syndrome research has focused on premature fusion of cranial sutures and craniofacial malformations ([@bib10]; [@bib22]; [@bib37]; [@bib23]; [@bib21]; [@bib20]), clinical traits that are consistently phenocopied in mouse models. However, little research has been carried out on the limb defects in Apert syndrome using the same animal models, mainly because most previous research reported that malformations of the limbs are subtle or absent in the different mouse models for Apert syndrome ([@bib8]; [@bib57]; [@bib58]). Contrary to these previous results, our quantitative morphometric analyses demonstrate that the limbs of *Fgfr2^+/P253R^* Apert syndrome mice have significant defects that are detectable in newborn mice and that can be traced back to early embryogenesis ([Figure 1](#fig1){ref-type="fig"}, [Figure 5](#fig5){ref-type="fig"} and [Figure 6](#fig6){ref-type="fig"}).

Our analyses provide insight into the genetic origins of these limb defects, showing that altered expression patterns of genes in the Fgf signaling pathway precede and contribute to limb dysmorphogenesis in *Fgfr2^+/P253R^* Apert syndrome mice. In fact, we detected that *Dusp6* expression patterns were different in unaffected and mutant littermates a few hours before the first limb dysmorphologies appeared ([Figure 5](#fig5){ref-type="fig"}), and confirmed that limb shape and *Dusp6* expression patterns were highly correlated ([Figure 6E](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). The altered Fgf signaling that was observed was due to the *Fgfr2* P253R Apert syndrome mutation, which causes loss of ligand specificity of the receptor and increased affinity of ligands for Fgfr2. As the Apert syndrome mutation is located in the linker region between the second and the third Ig-like domains of the receptor, and as alternative splicing of the protein occurs in the carboxy-terminal half of IgIII domain, the mutation affects both isoforms of the receptor, Fgfr2IIIb and Fgfr2IIIc ([@bib27]). Fgfr2IIIb is the isoform that is predominantly expressed in epithelial cells which normally binds to ligands produced in mesenchymal cells, whereas Fgfr2IIIc is expressed in mesenchymal cells and binds to ligands produced in epithelial cells. The available evidence indicates that Apert mutations alter this ligand specificity and thus raise the level of Fgfr2 signaling --- either through the aberrant interaction of mutant receptors with inappropriate ligands or through the upregulation of Fgfr2 ([@bib18]) and unpublished data). Our analyses showed that over-activation of the Fgf signaling pathway results in more expanded ([Figure 5E--G](#fig5){ref-type="fig"}) and larger ([Figure 6B](#fig6){ref-type="fig"}) expression domains for *Dusp6*, a gene that acts as a negative-feedback control of Fgf signaling ([@bib15]). A delay in misregulation of the expression of *Dusp6* may explain the lack of antero-posterior asymmetry and the shape deficiencies observed in *Fgfr2^+/P253R^* mutant mice ([Figure 5](#fig5){ref-type="fig"}). We found evidence that limb shape and *Dusp6* expression were highly associated ([Figure 6C--E](#fig6){ref-type="fig"}), but it is likely that other downstream genes of the Fgf signaling pathway also contribute to the limb shape malformations associated with Apert syndrome.

Our analyses also demonstrated that the embryonic limb defects persisted until birth ([Figure 1](#fig1){ref-type="fig"}) and thus did not disappear during development. For instance, we found that *Fgfr2^+/P253R^* Apert syndrome mice presented postnatal limb malformations involving the shape, length and volume of many bones of the forelimb, including the scapula, humerus, ulna, radius, metacarpals and phalanges ([Table 1](#table1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). It is not possible, however, to correlate early changes in limb bud shape directly to the defects in chondrogenesis and long bone length that appear later in development. The skeletal defects associated with Apert syndrome are the result of continuous altered Fgf signaling throughout growth and development. Overall, activated Fgf signaling may lead to decreased bone growth ([@bib35]). Our results demonstrate that *Dusp6* participates in this process, beginning very early in development, as do many other downstream targets of Fgf signaling that have different functions and spatio-temporal patterns, all of which are involved in the complex process that regulates limb morphogenesis. Although subtle, the first malformations detected in this study suggest that further research into the origins and causes of limb dysmorphologies in Apert syndrome using these and other mouse models is warranted.

Our quantitative approach could be similarly applied to investigate other developmental defects and dysmorphologies ([@bib60]). This is relevant as major developmental defects represent a leading cause of infant mortality and affect a small but relevant percentage of the population, severely compromising their quality of life ([@bib55]). OPT and GM can potentially be used to analyze any organ and animal model that can be visualized during development using light microscopy, and any gene whose gene expression pattern can be detected by WMISH and shows a continuous expression domain over development ([@bib38]). Our study is a proof of concept that demonstrates that this approach is feasible and develops a protocol that could be adjusted for the study of different genes and organs. With the current pipeline, the implementation of the approach should be straightforward and no more time- or resource-consuming than other cellular or molecular experiments. WMISH labeling is a standard technique in most molecular and developmental laboratories. OPT imaging is increasingly accessible and software for performing GM is freely available.

We exemplified the method by analyzing limb defects in mouse models, but it could be applied to malformations affecting the face, the brain, the tail, or any other organ that involves complex 3D shapes that are quantifiable with GM. Organs with morphologies that are devoid of reliable anatomical landmarks, such as the developing heart, should be analyzed with alternative non-landmark-based methods, such as spherical harmonics ([@bib52]). Moreover, the OPT-GM approach could be applied to other vertebrate animal models, such as zebrafish, chicken and *Xenopus*. Finally, our approach could also be extended to analyze protein expression patterns. Immunostaining labeling with a secondary antibody coupled to a BAAB-resistant fluorophore, such as Alexa, will reveal the expression pattern of proteins and this information can be precisely captured and quantified in 3D using the OPT-GM approach.

The limitation of the approach is the requirement to generate large samples of wildtype and mutant mice per gene and time point, since several WMISH labeling and OPT scanning activities cannot be performed within the same embryos. For high-throughput analyses assessing the expression of multiple genes, such as transcriptomic and microarray assays ([@bib62]), our OPT-GM approach is a complementary technique that could confirm whether the differences in the level of gene expression of candidate genes are associated with changes in the patterns of this expression (i.e. the regions within a tissue where the genes are expressed) and further phenotypic malformations. This type of quantitative analyses will lead to a deeper understanding of how development translates genetic into phenotypic variation.

Through its increased quantitative sensitivity, our method has allowed us to reveal that the mouse model for Apert syndrome does indeed show very early abnormalities in limb development. We detected that dysregulation of an *Fgfr2* target gene precedes measurable changes in limb bud morphology, thus identifying a relevant component of its genetic etiology. Quantitative evaluation of size and shape should thus be performed before discarding any animal models as useful for investigating human congenital malformations ([@bib66]). Our method has the potential to become a useful tool for biomedical research, providing insight into the processes that cause malformations and lead to malfunction, which is essential for understanding diseases and discovering potential therapies.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\     Designation          Source or reference            Identifiers                                                    Additional information
  (species) or\                                                                                                                        
  resource                                                                                                                             
  ----------------- -------------------- ------------------------------ -------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Genetic\          *Fgfr2^+/P253R^*     [@bib58];\                                                                                    Laboratory of Dr. Richtsmeier (Pennsylvania State University); inbred mouse model on a C57BL/6J background
  reagent\                               doi: 10.1186/1471\                                                                            
  (*M. musculus*)                        -213X-10--22                                                                                  

  Chemical\         PBST                 Sigma-Aldrich                  P3563                                                          Phosphate-buffered saline, 0.1% tween 20
  compound,\                                                                                                                           
  drug                                                                                                                                 

  Chemical\         paraformaldehyde     Sigma-Aldrich                  P6148                                                          4% in PBS
  compound,\                                                                                                                           
  drug                                                                                                                                 

  Chemical\         methanol             Sigma-Aldrich                  494437--2L-D                                                   Methanol for protein sequencing, bioReagent,99.93%
  compound,\                                                                                                                           
  drug                                                                                                                                 

  Chemical\         digoxigenin-UTP      Sigma-Aldrich                  11277073910                                                    DIG RNA Labeling Mix (Roche)
  compound,\                                                                                                                           
  drug                                                                                                                                 

  Sequence\         *Dusp6*              [@bib13]\                                                                                     m Mkp3-pCVM.sport6
  -based\                                doi:10.1016/S0925\                                                                            
  reagent                                -4773 (02)00024--2                                                                            

  Antibody          anti-DIG-AP\         Sigma-Aldrich                  11093274910                                                    (1:2000)
                    (sheep polyclonal)                                                                                                 

  Other             NBT                  Sigma-Aldrich                  11585029001                                                    4-nitro blue tetrazolium chloride, crystals (Roche)

  Other             BCIP                 Sigma-Aldrich                  11383221001                                                    4-toluidine salt (Roche)

  Chemical\         BABB                 Sigma-Aldrich                  402834; W213802                                                (one benzyl alcohol:two benzyl benzoate)
  compound,\                                                                                                                           
  drug                                                                                                                                 

  Chemical\         agarose              Sigma-Aldrich                  A9414                                                          Agarose low gelling temperature
  compound,\                                                                                                                           
  drug                                                                                                                                 

  Software,\        Matlab               The MathWorks, Inc             RRID:[SCR_001622](https://scicrunch.org/resolver/SCR_001622)   <https://es.mathworks.com/products/matlab.html>
  algorithm                                                                                                                            

  Software,\        R, CRAN              [@bib44]                       RRID:[SCR_003005](https://scicrunch.org/resolver/SCR_003005)   <http://www.R-project.org/>
  algorithm                                                                                                                            

  Software,\        Amira 6.3            FEI                            RRID:[SCR_014305](https://scicrunch.org/resolver/SCR_014305)   <https://www.fei.com/software/amira-3d-for-life-sciences/>
  algorithm                                                                                                                            

  Software,\        Viewbox              dHAL software,\                RRID:[SCR_016481](https://scicrunch.org/resolver/SCR_016481)   <http://www.dhal.com/>
  algorithm                              Kifissia, Greece                                                                              

  Software,\        Geomorph             [@bib1];\                      RRID:[SCR_016482](https://scicrunch.org/resolver/SCR_016482)   <https://cran.r-project.org/web/packages/geomorph/index.html>
  algorithm                              doi: 10.1111/2041-210X.12035                                                                  

  Software,\        MorphoJ              [@bib34]:\                     RRID:[SCR_016483](https://scicrunch.org/resolver/SCR_016483)   <http://www.flywings.org.uk/morphoj_page.htm>
  algorithm                              doi: 10.1111/j.1755\                                                                          
                                         --0998.2010.02924.x                                                                           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mouse model {#s4-1}
-----------

We analyzed the *Fgfr2^+/P253R^* Apert syndrome mouse model, an inbred model backcrossed on the C57BL/6J genetic background for more than ten generations, which carries a mutation that in humans with Apert syndrome is associated with more severe syndactyly. This gain-of-function mutation, which is embryonically lethal in homozygosis, involves a proline to arginine amino acid change at position 253 of the *Fgfr2* protein, which alters the ligand-binding specificity of the receptor and causes stronger receptor signaling. Further details of the mouse model and on the generation of targeting construct can be found elsewhere ([@bib58]). All the experiments were performed in compliance with the animal welfare guidelines approved by the Pennsylvania State University Animal Care and Use Committees (IACUC46558, IBC46590).

Micro-CT imaging {#s4-2}
----------------

High-resolution micro-computed tomography (μCT) scans were acquired by the Center for Quantitative Imaging at the Pennsylvania State University ([www.cqi.psu.edu](http://www.cqi.psu.edu)) using the HD-600 OMNI-X high-resolution X-ray computed tomography system (Varian Medical Systems, Palo Alto, CA). Pixel sizes ranged from 0.01487 to 0.01503 mm, and all slice thicknesses were 0.016 mm. Image data were reconstructed on a 1024 × 1024 pixel grid as a 16-bit TIFF. To reconstruct forelimb morphology from the μCT images, isosurfaces were produced with median image filter using the software package Avizo 6.3 (Visualization Sciences Group, VSG) ([Figure 1A--F](#fig1){ref-type="fig"}).

Morphometrics in P0 mice {#s4-3}
------------------------

We assessed forelimb morphology at P0 using unaffected (N = 10) and mutant (N = 12) littermates of Apert syndrome mouse models. A selection of 54 landmarks was collected on the left forelimb of all P0 mice, as shown in [Figure 1B--F](#fig1){ref-type="fig"}, following anatomical criteria selected to best describe the size and shape of forelimb bones in a reliable and reproducible manner. Landmarks at the proximal and distal tips of the phalanges, metacarpals, radius, ulna and clavicle were collected to represent the simple tubular shape of these bones. Additional landmarks were collected in anatomical structures of the humerus and scapula to better represent their complex 3D shapes ([Figure 1B--F](#fig1){ref-type="fig"}). To minimize measurement error, each landmark was collected twice by the same observer, restricting the deviations between the two trials to 0.05 mm.

At P0, we estimated the dimensions of the long bones of the forelimbs using the 3D coordinates of the landmarks located at the proximal and distal ends of the bones ([Figure 1B--F](#fig1){ref-type="fig"}). We also estimated the bone volumes from volume data collected from the microCT scans. To assess size differences in bone length and bone volume between mutant and unaffected P0 mice of the *Fgfr2^+/P253R^* Apert syndrome mouse model, we performed a two-tailed one-way ANOVA on those variables showing a normal distribution, and the non-parametric Mann-Whitney U-Test on those variables that deviated from a normal distribution. The shape of the humerus and the scapula was comparatively assessed in unaffected and *Fgfr2^+/P253R^* Apert syndrome littermates using Geometric Morphometrics.

Shape information was extracted using a Generalized Procrustes Analysis (GPA) ([@bib46]), in which configurations of landmarks are superimposed by shifting them to a common position, rotating and scaling them to a standard size until a best fit of corresponding landmarks is achieved ([@bib14]). The resulting Procrustes coordinates from the GPA were the input for further statistical analysis to compare the shape of the bones in unaffected and *Fgfr2^+/P253R^* mice. A Principal Component Analysis (PCA) was used to explore the morphological variation within each bone. PCA performs an orthogonal decomposition of the data and transforms variance covariance matrices into a smaller number of uncorrelated variables called Principal Components (PCs), which successively account for the largest amount of variation in the data ([@bib19]). Each specimen is scored for every Principal Component and the specimens can be plotted using these scores along the morphospace defined by the principal axes.

WMISH and OPT scanning {#s4-4}
----------------------

To examine early embryonic mouse limb development in Apert syndrome mice, we bred four litters of the *Fgfr2^+/P253R^* Apert syndrome mouse model and collected them between E10.5 and E11.5. In total, 32 mouse embryos were harvested and classified by PCR genotyping into unaffected (N = 16) and mutant (N = 16) littermates (see [Table 2](#table2){ref-type="table"} and [Figure 4](#fig4){ref-type="fig"} for further details on sample size and composition). We analyzed the maximum number of samples that we could process simultaneously within the same WMISH batch, as explained next.

*Dusp6* gene expression was assessed by whole-mount-in-situ hybridization (WMISH). Mouse embryos were dissected in cold phosphate-buffered saline, 0.1% tween 20 (PBST), fixed overnight in 4% paraformaldehyde (Sigma), dehydrated in a graded PBST/methanol series and stored at --20°C in methanol. The mouse embryos recovered their original size after rehydration in decreasing series of methanol/PBST. WMISH was carried out using *Dusp6* antisense RNA probes labeled with digoxigenin-UTP (Roche), following standard protocols ([@bib12]). Alkaline phosphatase coupled anti-digoxigenin (anti-DIG-AP, Roche) and NBT/BCIP staining (Roche) were used to reveal the expression pattern for *Dusp6*. To minimize variations during experimental procedures, all embryos were processed systematically within the same batch, processing unaffected and mutant littermates from different litters in separate tubes, but simultaneously using the same probe, timings and concentration reagents.

After embedding in agarose, dehydrating in methanol and chemically clearing the samples with benzyl alcohol and benzyl benzoate (BABB), the stained whole embryos were scanned with both fluorescence and transmission light with a cyan fluorescent protein (CFP) filter using our home-built OPT imaging system mounted on a Leica MZ 16 FA microscope ([@bib50]). The embryos were 3D-reconstructed from the resulting 2D images using Matlab (The MathWorks, Inc.) and visualized using Amira 6.3 (Visualization Sciences Group, FEI). From the OPT fluorescence scans, we produced 3D reconstructions of the embryo surface and we dissected the available right and left fore- and hindlimbs of each specimen, resulting in a sample of 100 embryonic limbs ([Table 2](#table2){ref-type="table"}). From the OPT transmission scans, we recovered the *Dusp6* expression domain. As *Dusp6* is expressed in a fuzzy spatial gradient, as already shown by other genes ([@bib38]), we used 3D multiple thresholding to visualize the gene expression domain at different intensities ([Figure 3](#fig3){ref-type="fig"}). To analyze the gene expression domains comparatively across the samples, we inspected the whole range of threshold values under which the gene expression could be visualized for each limb, from the threshold showing its first appearance to the threshold under which it disappeared and was no longer detectable. We analyzed the 3D reconstruction on the basis of a threshold computed as 1/3 that of the last grey value showing the *Dusp6* expression domain, which displayed a *Dusp6* domain at high gene expression ([Figure 3](#fig3){ref-type="fig"}, step 3). Finally, we obtained 80 limbs (46 forelimbs and 34 hindlimbs) with associated gene expression patterns for *Dusp6.* Limbs or gene expression domains that were damaged during experimental manipulation or which showed obvious artifacts resulting from altered staining or imaging were discarded from the analyses. Outlier points were detected following standard protocols in GM that are based on squared Procrustes distance, and landmark misplacements were fixed whenever possible.

Embryo staging {#s4-5}
--------------

To account for breeding and developmental variation, individual limb buds were staged using our publicly available web-based staging system (<https://limbstaging.embl.es>) ([@bib42]). Considering the spline curve along the outline of the limb, this tool provides a stage estimate with a reproducibility of ±2 hr. According to the staging results, the different mouse litters were ordered following a continuous temporal sequence from E10 to E11.5 ([Table 2](#table2){ref-type="table"} and [Figure 4](#fig4){ref-type="fig"}). To minimize high developmental variation within and among litters of mice, hindlimbs and forelimbs from each litter were analyzed separately, except for those from two litters from the earliest stage that were pooled into the same group because their temporal distribution completely overlapped, as shown in [Figure 4](#fig4){ref-type="fig"}.

Morphometrics from E10 to E11.5 {#s4-6}
-------------------------------

To capture the size and shape of the limbs and the expression domains of *Dusp6,* we collected a set of anatomical landmarks as well as curve and surface semi-landmarks ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), as recommended in structures devoid of homologous landmarks. Semi-landmarks are mathematical points located along a curve ([@bib5]) or a surface ([@bib17]) within the same object that can be slid to corresponding equally spaced locations across the sample. Only five anatomical landmarks were discernible in the limb, and four in the *Dusp6* expression pattern ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). We defined several curves and surfaces over the limb as well as gene expression structures with a relatively low number of semi-landmarks in order to minimize the high dimensionality of the data while providing an adequate shape coverage that precisely captured the subtle morphological changes associated with the Apert syndrome mutation. We used Amira 6.3 (Visualization Sciences Group, FEI) to record the anatomical landmarks and Viewbox 4 (dHAL software, Kifissia, Greece) to construct a limb template of surface and curve semi-landmarks and to interpolate them onto each target shape ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

The 3D landmark coordinates defining the shape of the limb and the *Dusp6* expression domain were analyzed using Procrustes-based landmark analysis ([@bib5]). Semi-landmarks were allowed to slide in the GPA by minimizing the bending energy ([@bib5]; [@bib17]; [@bib41]). Quantitative shape analyses based on PCA were performed as explained above.

We estimated the size of the limb as the centroid size, calculated as the square root of the summed squared distances between each landmark coordinate and the centroid of the limb configuration of landmarks ([@bib14]). The volumes of the *Dusp6* domains were estimated from the 3D reconstructions of the OPT scans. Differences in limb size and gene expression volume between mutant and unaffected embryonic mice were tested for statistical significance using a two-tailed Welch Two Sample t-test.

We quantified the integration between the limb and the *Dusp6* expression pattern and produced visualizations of the patterns of associated shape changes between them using two-block Partial Least Squares analysis (PLS) ([@bib45]). This method performs a singular value decomposition of the covariance matrix between the two blocks of shape data (i.e., the limb and the *Dusp6* expression domain). Uncorrelated pairs of new axes are derived as linear combinations of the original variables, with the first pair accounting for the largest amount of inter-block covariation, the second pair for the next largest amount and so on. The amount of covariation is measured by the RV coefficient, which is a multivariate analogue of the squared correlation ([@bib32]). Statistical significance was tested using permutation tests under the null hypothesis of complete independence between the two blocks of variables. Separate analyses for each developmental period, as well as for forelimbs and hindlimbs of all stages, were computed.

All of the analyses were performed using R ([@bib44]; <http://www.R-project.org>); the R package geomorph ([@bib1]; <http://cran.r-project.org/web/packages/geomorph>), SPSS Statistics 22 (IMB, 2013) and MorphoJ ([@bib34]).

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/501100000780European Commission FP7‐PEOPLE‐2012‐ 597 IIF 327382 to Neus Martínez-Abadías.

-   http://dx.doi.org/10.13039/100000002National Institutes of Health NICHD P01HD078233 to Joan Richtsmeier.

-   http://dx.doi.org/10.13039/100000002National Institutes of Health NIDCR R01DE02298 to Joan Richtsmeier.

-   http://dx.doi.org/10.13039/100000861Burroughs Wellcome Fund 2013 Collaborative Research Travel Grant to Joan Richtsmeier.

We acknowledge support of the Spanish Ministry of Economy and Competitiveness provided to the EMBL partnership and the 'Centro de Excelencia Severo Ochoa', as well as support from the CERCA Programme/Generalitat de Catalunya. We thank Ethylin Wang Jabs for access to the *Fgfr2^+/P253R^* Apert syndrome mouse model. The research leading to these results received funding from the following grants: a European Union Seventh Framework Program (FP7/2007-2013) under grant agreement Marie Curie Fellowship FP7-PEOPLE-2012-IIF 327382, National Institutes of Health grants NICHD P01HD078233 and NIDCR R01DE02298, and a Burroughs-Welcome Fund 2013 Collaborative Research Travel Grant.

Additional information {#s5}
======================

No competing interests declared.

Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing---original draft, Project administration.

Formal analysis, Methodology, Writing---review and editing.

Formal analysis, Methodology, Writing---review and editing.

Data curation, Formal analysis, Supervision, Methodology, Writing---review and editing.

Formal analysis, Methodology.

Visualization, Methodology, Writing---review and editing.

Visualization, Methodology, Writing---review and editing.

Visualization, Methodology.

Methodology, Writing---review and editing.

Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Project administration, Writing---review and editing.

Conceptualization, Supervision, Funding acquisition, Project administration, Writing---review and editing.

Animal experimentation: All the experiments were performed in compliance with the animal welfare guidelines approved by the Pennsylvania State University Animal Care and Use Committees (IACUC46558, IBC46590).

Additional files {#s6}
================

10.7554/eLife.36405.027

Data availability {#s7}
-----------------

Our dataset has been deposited to Dryad (<http://dx.doi.org/10.5061/dryad.8h646s0>).

The following dataset was generated:

Martinez-Abadias NEstivill RMTomas JSPerrine SMYoon MRobert-Moreno ASwoger JRusso LKawasaki KRichtsmeier JSharpe J2018Data from: Quantification of gene expression patterns to reveal the origins of abnormal morphogenesis<http://dx.doi.org/10.5061/dryad.8h646s0>Available at Dryad Digital Repository under a CC0 Public Domain Dedication

10.7554/eLife.36405.031

Decision letter

Rosen

Clifford J

Reviewing Editor

Maine Medical Center Research Institute

United States

Haelterman

Nele A

Reviewer

Baylor College of Medicine

United States

Lyons

Karen

Reviewer

University of California, Los Angeles

Los Angeles

United States

Brooks

Susan

Reviewer

University of Michigan

Michigan

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Quantification of gene expression patterns to reveal the origins of abnormal morphogenesis\" for consideration by *eLife*. Your article has been reviewed by Marianne Bronner as the Senior Editor, a Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Nele A Haelterman (Reviewer \#1); Karen Lyons (Reviewer \#2); Susan Brooks (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The reviewers and editors were enthusiastic about the optical projection techniques coupled with gene expression that should provide new insights with other mutant strains, although there was some question about how frequently this methodology could be employed in other laboratories. The method was clearly able to identify morphological anomalies earlier in development than previously recognized in the context of the *Fgfr2* mutation and the relationship of those changes to *Dusp6* expression. There were however some concerns which need to be discussed in the revision. In particular these were related to *Dusp6* functional data and the correlation with limb size. Other comments are noted below and should be addressed.

*Reviewer \#1:*

Summary:

Revealing the pathogenic mechanism that causes a developmental disorder typically requires phenotypic characterization of model organisms that are mutant for the homolog of the causative human gene. When such mutation induces a subtle phenotype, it is quite challenging to identify the changes, making it practically impossible to tease out the underlying pathogenic mechanisms.

In the current manuscript, Martinez-Abadias et al. combine multiple methods (whole mount in situ hybridization, optical projection tomography and geometric morphometrics) to quantify subtle changes in the morphology and gene expression of *Fgfr2^+/P253R^* mutant limb buds. Whereas previous studies failed to identify significant changes in limb development in these mutants, the method developed by Martinez-Abadias et al. allowed for a more in-depth analysis, revealing subtle, but significant changes between the limbs of *Fgfr2^+/P253R^* mutants and their wildtype littermates. The authors next describe similar subtle, but significant changes in the expression pattern of a downstream target of the *FGFR2: Dusp6*.

This is a well-written manuscript that presents a novel method to quantify gene expression patterns in 3D. In my opinion, it provides a significant advance to the field, as it is not simple to quantify expression patterns and pinpoint changes in 3D, even if these changes are large.

Essential revisions:

1\) This is an interesting new technology to identify modest changes in morphology of a developing organ or body part. However, I am not convinced it is feasible to perform these experiments at a higher throughput to analyze the expression pattern of multiple genes and be able to truly dissect out which genes have altered expression patterns in a mutant. The method appears to be quite labor intensive. Does one need to limit themselves to analyzing one or two candidate genes whose expression is already thought to be altered? Currently, the authors show a proof of concept of one gene. Could the authors comment on the time it took or would take to analyze the expression pattern of a novel gene, assuming the WISH is already optimized?

2\) The authors reveal an expansion of the *Dusp6* expression domain in developing mutant limb buds and show a high correlation between the shape of the limb and the shape of the *Dusp6* domain. However, based on the presented data, the statement that \"This is evidence that altered *Fgf* signaling induced by the *Fgfr2* P253R Apert syndrome mutation will have a direct effect on the limb phenotype" (subsection "Altered *Dusp6* expression and limb dysmorphology are highly associated") is an overstatement. The authors show a correlation, but to definitively show that altered *Dusp6* expression and/or *Fgf* signaling is causative, functional data is required. Does normalizing the *Dusp6* expression domain, or normalizing *FGFR2* function in these mutant mice rescue the observed phenotypes? If the authors have such data, it should be added to the manuscript. If not, this statement should be toned down in subsection "Altered *Dusp6* expression and limb dysmorphology are highly associated" and elsewhere in the manuscript.

*Reviewer \#2:*

This manuscript describes the use of optical projection tomography (OPT) and geometric morphometrics (GM) to address one of the biggest challenges in relating genotype to phenotypic outcome. I am not an expert on OPT or GM, and cannot evaluate the technical details in this manuscript. However, this group has done foundational studies in this area, described the methodology in detail, and has provided all source data. This will enable other groups to replicate the analysis and compare it with other methods in the future.

There are other studies using both GM and OPT from this group and others. Experts in these techniques will need to weigh in on the technical novelty in this manuscript. The conceptual novelty here is to apply these methodologies to quantify and changes in gene expression and relate these to changes in form. The analysis assesses variation within a genotype and relates this to variation in stages of development. This is powerful. The analysis also firmly establishes differences in gene expression and form based on *FGFR2*genotype. Neither of these insights are possible using standard histological or morphological analysis, and from my limited knowledge, is a serious challenge even for experts in quantitative 3D analysis. Therefore, this report is an important demonstration. The results demonstrate that effects on *Dusp6* expression can be seen in limb buds of *Fgfr2 P253R* mice. This is an interesting and important finding. It is also highly plausible. It opens the door to finding how the expression domain of *FGFR2* in normal and mutant limb buds intersects with that of *Dusp6*. It is less clear how, or if, these early changes in limb bud shape relate to the defects in chondrogenesis and long bone length, since *FGFR2* is continuously expressed in skeletal tissues.

The data are extensive and clearly presented, even to this reviewer, who does not have expertise with the types of analysis that are employed. Some of the data in the figures are replicated in the supplemental figures, but this is helpful to follow the logic. While the typical laboratory would not be able to establish this methodology, the study could inspire very insightful collaborations, and should inform the larger publicly supported efforts to catalog both gene expression and mutant phenotypes.

In summary, the main value of the study lies in its promise as a methodology to quantify gene expression changes and relate these to subtle morphological outcomes.

*Reviewer \#3:*

The manuscript describes an application of a new methodology correlating spatially mapped quantitative gene expression data with shape changes to examine the development of skeletal abnormalities. Specifically, mice possessing a mutation in the *Fgfr2* gene were analyzed for forelimb development and expression of *Dusp6*, a target of *Fgf* signaling. The method was able to identify morphological anomalies earlier in development than previously recognized in the context of the *Fgfr2* mutation and the relationship of those changes to *Dusp6* expression.

The paper is well-written and the data are clearly presented. Clarification of some methods and additional discussion of a few points would improve the manuscript.

How were the landmarks on the forelimb bones chosen? Are these defined elsewhere or did the authors choose them for this work specifically? In the latter case, what provided the rationale for the choices? Similarly, please describe how the markers for the limb and gene landmarking were determined.

Subsection "Altered *Dusp6* expression and limb dysmorphology are highly associated". The authors characterize the correlations between *Dusp6* expression and limb size as moderate, but the R2 values indicate that \~50% of the variation in limb size is explained by *Dusp6* expression. This actually seems quite large for a single gene. In the same discussion, the authors describe *Dusp6* gene expression\'s dependency on limb size. Is the directionality of the relationship from size to *Dusp6* expression or is it changes in *Dusp6* expression that partially determine limb size?

Discussion section. The authors indicated that the approach could be similarly applied to other developmental defects in other organ systems. A discussion of which tissues or organs are particular amenable to this method or may be particularly problematic would be an interesting addition.

10.7554/eLife.36405.032

Author response

> The reviewers and editors were enthusiastic about the optical projection techniques coupled with gene expression that should provide new insights with other mutant strains, although there was some question about how frequently this methodology could be employed in other laboratories.

We really appreciate all the positive feedback from the editors and reviewers and we are glad to share their enthusiasm. We acknowledge that the potential applications of our method in other laboratories, working with other genes or organs, was not sufficiently explained in the previous version of the manuscript. In this review, we have expanded the Discussion section to address this issue and provide more examples in which our method could be directly applied to address questions of interest to a wide range of researchers.

> The method was clearly able to identify morphological anomalies earlier in development than previously recognized in the context of the Fgfr2 mutation and the relationship of those changes to Dusp6 expression. There were however some concerns which need to be discussed in the revision. In particular these were related to Dusp6 functional data and the correlation with limb size. Other comments are noted below and should be addressed.

See response to each of these issues below and corresponding changes in the main text (Results section).

> Reviewer \#1:
>
> \[...\]
>
> Essential revisions:
>
> 1\) This is an interesting new technology to identify modest changes in morphology of a developing organ or body part. However, I am not convinced it is feasible to perform these experiments at a higher throughput to analyze the expression pattern of multiple genes and be able to truly dissect out which genes have altered expression patterns in a mutant.

Our study was a proof of concept to demonstrate that this approach was feasible and to establish a basic protocol that could later be adjusted to different genes and organs. We agree with the reviewer that once we have demonstrated the potential of the method, the next step would be to leverage the method to perform higher throughput analyses. The current method should be readily extended to other organs, genes and/or species provided that their shapes are well-defined with at least some reliably recognizable landmarks, and the genes can be labeled by WMISH (Martínez-Abadías et al., 2016).

The bottleneck is, however, the generation of so many mouse embryos to achieve large wildtype and mutant mouse samples per gene and time point. Unfortunately, it is technically not possible to perform several WMISH labeling and OPT scanning within the same embryos. Therefore, rather than using the OPT-GM method as an exploratory technique to analyze the expression pattern of myriad of genes, it is more plausible to use the OPT-GM as a method to confirm whether the expression patterns of candidate genes that have been identified using other molecular techniques, such as transcriptomics, are altered and can be associated with phenotypic malformations. This type of quantitative analyses is the only way that will lead to a deeper understanding of how development translates genetic into phenotypic variation. This knowledge will be essential in the future for understanding diseases and discovering potential therapies that can be introduced just before the first alterations appear. This issue is further discussed now in the main text of the manuscript. Please, see the Discussion section.

> The method appears to be quite labor intensive. Does one need to limit themselves to analyzing one or two candidate genes whose expression is already thought to be altered? Currently, the authors show a proof of concept of one gene. Could the authors comment on the time it took or would take to analyze the expression pattern of a novel gene, assuming the WISH is already optimized?

The manuscript reflects how labor intensive it was to develop the technique for the first time. Now that the experimentation, imaging, segmentation and landmark processing of the samples have all been optimized, and are explained in full detail in the paper, a similar sample as the one used in this study could be processed in several weeks. The number of genes to be assessed will depend on the intrinsic nature of the investigation and the available resources.

One of the main apparent difficulties to implement the OPT-GM method might be the lack of familiarity with Geometric Morphometrics (GM) within the Developmental Biology field. However, GM is currently used in many laboratories to analyze the patterns of morphological variation in all types of organisms (Klingenberg, 2010). Thanks to the growing interest in this technique, many resources are available to learn and perform GM studies (http://life.bio.sunysb.edu/morph/index.html). Actually, all the analyses in this study have been performed using freely available software and scripts that were rewritten to automatize the process, as for example *Fiji* (Fiji is just ImageJ) and R packages especially suited to GM, such as geomorph.

An extended discussion on these issues can be found at the following link:

https://prelights.biologists.com/highlights/quantification-gene-expression-patterns-reveal-origins-abnormal-morphogenesis/

This issue has been dealt with in the text in the Discussion section.

> 2\) The authors reveal an expansion of the Dusp6 expression domain in developing mutant limb buds and show a high correlation between the shape of the limb and the shape of the Dusp6 domain. However, based on the presented data, the statement that \"This is evidence that altered Fgf signaling induced by the Fgfr2 P253R Apert syndrome mutation will have a direct effect on the limb phenotype (subsection "Altered Dusp6 expression and limb dysmorphology are highly associated") is an overstatement. The authors show a correlation, but to definitively show that altered Dusp6 expression and/or Fgf signaling is causative, functional data is required. Does normalizing the Dusp6 expression domain, or normalizing FGFR2 function in these mutant mice rescue the observed phenotypes? If the authors have such data, it should be added to the manuscript. If not, this statement should be toned down in subsection "Altered Dusp6 expression and limb dysmorphology are highly associated"and elsewhere in the manuscript.

We acknowledge that the sentence in subsection "Altered *Dusp6* expression and limb dysmorphology are highly associated" is an overstatement. Correlation is not causation and functional data is not available, as we have not tested any means to normalize Dups6 expression or *FGFR2* function in these mice. Therefore, we have toned it down accordingly -- we now say "This is evidence that altered *Fgf* signaling induced by the *Fgfr2* P253R Apert syndrome mutation can be associated with limb dysmorphology". Please, see change in subsection "Altered *Dusp6* expression and limb dysmorphology are highly associated".

> Reviewer \#2:
>
> This manuscript describes the use of optical projection tomography (OPT) and geometric morphometrics (GM) to address one of the biggest challenges in relating genotype to phenotypic outcome. I am not an expert on OPT or GM, and cannot evaluate the technical details in this manuscript. However, this group has done foundational studies in this area, described the methodology in detail, and has provided all source data. This will enable other groups to replicate the analysis and compare it with other methods in the future.
>
> There are other studies using both GM and OPT from this group and others. Experts in these techniques will need to weigh in on the technical novelty in this manuscript. The conceptual novelty here is to apply these methodologies to quantify and changes in gene expression and relate these to changes in form. The analysis assesses variation within a genotype and relates this to variation in stages of development. This is powerful. The analysis also firmly establishes differences in gene expression and form based on FGFR2 genotype. Neither of these insights are possible using standard histological or morphological analysis, and from my limited knowledge, is a serious challenge even for experts in quantitative 3D analysis. Therefore, this report is an important demonstration. The results demonstrate that effects on Dusp6 expression can be seen in limb buds of FGFR2 P253R mice. This is an interesting and important finding. It is also highly plausible. It opens the door to finding how the expression domain of FGFR2 in normal and mutant limb buds intersects with that of Dusp6. It is less clear how, or if, these early changes in limb bud shape relate to the defects in chondrogenesis and long bone length, since FGFR2 is continuously expressed in skeletal tissues.

As correctly pointed out by the reviewer, we cannot correlate early changes in limb bud shape to the defects in chondrogenesis and long bone length. Indeed, the skeletal defects associated with Apert syndrome are the result of continuous altered *FGF/FGF*R signaling throughout growth and development. However, this was not the goal of our study -- our goal was to determine whether we could find subtle early changes in gene expression (and limb bud shape) before any phenotype could be detected by eye. Our results demonstrate that our method is able to identify the first moment in which limb malformation and altered *Dusp6* expression arises. However, our results do not imply that limb dysmorphologies are caused only by altered expression of *Dusp6* in E10.5. Besides *Dusp6*, many other downstream targets of *Fgf* signaling must be involved in this complex process regulating limb morphogenesis. This has been addressed in the Discussion section.

> The data are extensive and clearly presented, even to this reviewer, who does not have expertise with the types of analysis that are employed. Some of the data in the figures are replicated in the supplemental figures, but this is helpful to follow the logic. While the typical laboratory would not be able to establish this methodology, the study could inspire very insightful collaborations, and should inform the larger publically supported efforts to catalog both gene expression and mutant phenotypes.
>
> In summary, the main value of the study lies in its promise as a methodology to quantify gene expression changes and relate these to subtle morphological outcomes.

We really appreciate the reviewer's enthusiastic overall comment about our study.

> Reviewer \#3:
>
> \[...\]
>
> The paper is well-written and the data are clearly presented. Clarification of some methods and additional discussion of a few points would improve the manuscript.
>
> How were the landmarks on the forelimb bones chosen? Are these defined elsewhere or did the authors choose them for this work specifically? In the latter case, what provided the rationale for the choices? Similarly, please describe how the markers for the limb and gene landmarking were determined.

The landmarks on the forelimb bones were chosen by us for this work specifically following anatomical criteria to best describe their size and shape in a reliable and reproducible manner. Indeed, one of the main advantages of GM is that each study is unique and can be personalized to meet the requirements of the analysis. The set of landmarks used to capture the shape of the object/organism under study is always chosen by the investigators. The definitions of many anatomical landmarks can be found in the literature, but additional new landmarks can be used by the researchers whenever a clear definition is provided to ensure the reproducibility of the study. Below we provide further explanation about how we chose our set of landmarks.

For the hand, clavicle and forearm bones (radius and ulna), as they present simple tubular shapes, we just collected the landmarks at the proximal and distal tips of the bones, as shown in Figure 1 and explained in the figure legend. From the 3D coordinates of these landmarks, we could estimate total bone length by applying the Pythagorean Theorem. In the case of the humerus, besides the landmarks at the proximal and distal tips, we also collected a landmark at the tip of the deltoid process, which is an additional readily recognizable feature of this bone. Finally, in the case of the scapula, which presents a more complex 3D shape, we captured its morphology by precisely registering the 3D coordinates of points defined by anatomical structures of the scapula, such as the spine, the acromion process and the glenoid cavity.

In GM, this type of homologous anatomical landmarks are the basis of a rigorous quantitative shape analysis. Anatomical landmarks can be combined with the so-called semilandmarks, which are points located along a curve or a surface that can be slid to corresponding equally spaced locations (Gunz, Mitteroecker, and Bookstein, 2005). This is an approach widely applied in structures presenting few homologous landmarks. As only five landmarks were discernable in the limb, and four in the *Dusp6* expression pattern, we defined several curves and surfaces over the limb and gene expression structures to precisely capture the subtle morphological changes associated with the Apert syndrome mutation. The number of semilandmarks is also chosen by the investigators, usually compromising between a good shape coverage and minimizing the high dimensionality of the data. Further details are provided in Figure 5---figure supplement 1. We have added some explanations regarding these topics in Materials and methods subsection "Morphometrics from E10 to E11.5".

> Subsection "Altered Dusp6 expression and limb dysmorphology are highly associated". The authors characterize the correlations between Dusp6 expression and limb size as moderate, but the R2 values indicate that \~50% of the variation in limb size is explained by Dusp6 expression. This actually seems quite large for a single gene. In the same discussion, the authors describe Dusp6 gene expression\'s dependency on limb size. Is the directionality of the relationship from size to Dusp6 expression or is it changes in Dusp6 expression that partially determine limb size?

Our results indicate that there is significant correlation between the limb morphology and the expression of *Dusp6*. However, we cannot conclude that the altered *Dusp6* expression causes the limb defects of Apert syndrome. The limb dysmorphology is likely the result of altered *Fgf* signaling that affects many downstream targets, including *Dusp6*, each with different functions and spatio-temporal patterns. With this method we can identify when phenotype and genetic alterations first appear and whether they are associated or independent from each other. However, we cannot quantify which percentage of the dysmorphology is due to an altered gene expression. We have added a sentence in the Discussion to more clearly explain this issue.

> Discussion section. The authors indicated that the approach could be similarly applied to other developmental defects in other organ systems. A discussion of which tissues or organs are particular amenable to this method or may be particularly problematic would be an interesting addition.

The approach is indeed powerful and adaptable to other organs and model systems. The main limitation is the availability of gene probes to perform WMISH and the intrinsic shape of the organ and the gene expression domain to perform GM. Geometric Morphometrics is based on the location of at least a few points that can be reliably located in all the samples. Thus, GM is difficult to apply in structures such as the developing heart, which in its first stages is just a twisting tube. GM is particularly amenable to more complex 3D shapes, such as the facial prominences, the brain and the limbs. In addition, it could be applied in different animals' models, such as zebra fish, chicken and*Xenopus.*

We hope other investigators will apply our approach and discovering new processes and mechanisms that cannot simply by detected qualitatively by eye. Whole mount in situ hybridization (WMISH) is a technique that is already in use in most molecular labs around the world. Many groups may already have data on gene expression patterns ready to be quantified. Geometric morphometrics (GM) is also a discipline within everyone's reach, with a long history, plenty of available resources, user-friendly free software and a big community of users (www.morphometrics.org). This discussion can be found in the revised version of the manuscript in the Discussion section,
